Benjamin Samelson-Jones, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, discusses a recent analysis evaluating changes in joint health in patients with hemophilia following treatment with dirloctocogene samoparvovec, an adeno-associated virus (AAV)-based gene therapy. Joint health was measured using two standardized scores: the Hemophilia Joint Health Score (HJHS) and the Hemophilia Activities List (HAL). Dr Samelson-Jones shares the results of both scoring systems, highlighting that patients with a low HAL score at baseline showed more marked improvements following treatment. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть